4277. Package #129 (Cervical screening: PAP test using liquid cytology (BD SurePath technology, FDA approved). CYTOLOGICAL PASSPORT (BD FocalPoint technology, FDA approved), PCR. HPV HCR 14 genotypes, quantitative determination)
Turnaround time (days): 3
1650 ₴
Important information
*FOR WOMEN ONLY
*An operator specifies the day of the menstrual cycle or the gestational age
*For the test ordering a special doctor's referral is required
Description
Package No. 129 combines two modern methods of cervical screening that allow for the most accurate assessment of cervical health: Pap test using the BD SurePath™ liquid-based cytology method with additional automated analysis via BD FocalPoint™ (Cytology Passport) – a state-of-the-art, high-precision technology for early detection of precancerous and malignant cervical changes.
At Synevo, the study is performed using a dual-review approach:
- by experienced cytologists;
- using the BD FocalPoint™ GS Imaging System (Becton Dickinson, USA) based on artificial intelligence, combined with a ZEISS Axioscope 5 microscope (Carl Zeiss, Germany).
This approach significantly increases the sensitivity and reliability of detecting pathological changes. The test allows the identification of epithelial cells showing signs of precancerous or malignant transformation at early stages, when treatment is most effective. PCR test for high-risk human papillomavirus (HPV) (14 genotypes) with quantitative determination – a modern method that detects HPV infection and measures viral load for the most oncogenic genotypes associated with cervical cancer. The combined approach makes it possible to simultaneously assess the morphological changes in cervical cells and detect high-risk HPV infection, thereby increasing diagnostic accuracy in line with current international standards (ASCCP, ESGO, WHO) and the Order of the Ministry of Health of Ukraine No. 1057 dated 18.06.2024.
In Ukraine, cervical cancer ranks among the top three most common cancers in women, which makes regular screening crucial for prevention and maintaining women’s health.
When and who needs the test?
- routine screening for women;
- after a positive HPV test or abnormal cytology results;
- after CIN treatment or conization to monitor treatment effectiveness;
- in cases of detected dysplasia, inflammatory changes, or STIs;
- to assess the risk of progression in persistent HPV infection.
Biological material
- Site-specific scrapings collected depending on the test
- Scrapes from various sites depending on the test
Preparing for urogenital sampling
- Collect the material before starting treatment with antibacterial/antifungal drugs (general and local action).
- In case of treatment monitoring – 14 days after the end of the course of treatment with antibacterial/antifungal drugs.
- Avoid sexual intercourse for 3 days.
- Exclude douching and the use of vaginal...